3 results
Approved WMORecruitment stopped
PRM-151 is being developed for potential therapeutic uses to prevent, treat, and reduce fibrosis. This study will provide an initial assessment of the safety, tolerability, and pharmacokinetics (PK) of PRM-151 after administration of ascending…
Approved WMORecruitment stopped
To demonstrate that treatment with drotrecogin alfa (activated) 24 mcg/kg/h administered as an intravenous infusion for 96 hours reduces 28 day all-cause mortality in adult patients with septic shock compared with placebo.
Approved WMOPending
As meeting protein requirements seems to be very important in critically ill patients, the primary objective of the current study is to investigate protein intake with the new tube feed.